Breast Cancer Therapy Market - Growth, Trends, and Forecasts (2023 - 2028)

The breast cancer therapy market is expected to record a CAGR of 8.3% over the forecast period (2022-2027).

Following the outbreak of COVID-19, the market has faced a slight setback, owing to the delay in diagnoses, shortages of drugs, and unavailability of healthcare professionals. According to an article published in the JAMA Network in August 2020, there was a significant decline in breast cancer diagnoses (51.8%) in United States between March 1, 2020, and April 18, 2020. This delay in diagnosis has impacted the treatment of the same. However, the market is expected to gain traction over the coming years as treatments resume worldwide.

The major factors fueling the market's growth are the high incidence and prevalence rates of breast cancer; increasing investment in research and development; and advancements in cancer biology and pharmacology, which are promoting drug development.

According to Globocan, in 2020, about 2,261,419 new cases of cancer were reported across the world, contributing to about 11.7% of the total cancer cases. As per Cancer Australia, in 2021, it was estimated that 20,030 new cases of breast cancer were diagnosed in the country (164 males and 19,866 females). The same source reports that in 2021, a person had an estimated 1 in 15 (or 6.7%) risk of being diagnosed with breast cancer by the age of 85 (1 in 8 or 13% for females and 1 in 829 or 0.12% for males). Therefore, the high burden of breast cancer is increasing the demand for breast cancer treatment, thereby contributing to the market's growth.

The increasing focus of research studies by the market players. For instance, in September 2021, Novartis collaborated with SOLTI Innovative Cancer Research (SOLTI) on HARMONIA, an international, randomized, Phase III, multicenter, and open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib), both in combination with endocrine therapy. This study was done on patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with a HER2-enriched (HER2E) intrinsic subtype.

Additionally, in July 2021, Arvinas Inc. and Pfizer Inc. collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers.

On the other hand, the risk of adverse effects of radiation exposure and stringent regulatory scenarios are hindering the market's growth.

Key Market Trends

Chemotherapy Segment Expected to Witness High Growth Over the Forecast Period

Chemotherapy is the most common form of therapy used to stop or slow down the growth of cancerous cells. It is the most common treatment for triple-negative breast cancer patients.

According to the Centers for Disease Control and Prevention, in a November 2021 update, nearly 650,000 cancer patients (including breast cancer patients) receive chemotherapy every year in United States. Thus, the growing number of patients receiving chemotherapy and the development of new products are expected to significantly contribute to the market's growth.

Furthermore, the number of product launches in this segment is expected to drive its growth. For instance, in July 2021, Merck, also known as MSD outside United States and Canada, announced that United States Food and Drug Administration (FDA) approved KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC). Based on Phase 3 KEYNOTE-522 trial, this is meant to be used in combination with chemotherapy as a neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery. Also, in May 2021, Zydus Cadila launched a next-generation breast cancer drug in India. The drug, Trastuzumab emtasine, is considered the first targeted chemotherapy drug for breast cancer.

Thus, owing to the abovementioned factors, the market segment is expected to show growth over the forecast period.

North America Expected to Dominate the Market Over the Forecast Period

Within North America, United States is expected to dominate the overall market throughout the forecast period. The major factors fueling the market's growth are the increasing burden of breast cancer in the country, growing awareness about breast cancer, and increasing product launches.

In United States, breast cancer is one of the leading cancer types. According to the January 2022 update by breastcancer.org, around 1 in 8 women in the country (about 13%) develop invasive breast cancer over their lifetime. The same source reports that, in 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in United States, as well as 51,400 new cases of non-invasive (in situ) breast cancer. As per the same source, about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022. A man's lifetime risk of breast cancer is about 1 in 833.

Furthermore, as per an October 2021 update by the University of North Carolina's School of Medicine, Susan G. Komen, the world's leading breast cancer organization, announced that it would award USD 1.5 million for three new research projects that examine three unique areas focused on metastatic breast cancer (MBC).

In April 2021, Gilead Sciences Inc. reported that United States Food and Drug Administration (FDA) granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Thus, due to the above-mentioned factors, the market in North America is expected to grow during the forecast period.

Competitive Landscape

The breast cancer therapy market is competitive and consists of several major and small players. Some of the major players in the market are Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Eisai Co. Ltd., and Merck & Co. Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support